Neoadjuvant therapy–associated malignant phenotype score predicts prognosis and highlights the roles of MIF signaling and DUXAP8 in ESCC
BackgroundEsophageal squamous cell carcinoma (ESCC) remains a major malignancy globally, and long-term survival outcomes remain poor despite advances in multimodal treatment strategies. Neoadjuvant therapy (NAT) has become the standard of care for resectable ESCC; however, substantial interpatient h...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2026-01-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1683349/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|